ASCO 2016: Dr. Roxana Dronca’s Recommended Abstracts—Melanoma
Melanoma/Skin Cancers
Saturday June 4, 2016; 1:00 PM–4:30 PM
TPS9591 A Randomized Phase 2 Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients (Pts) With Melanoma Brain Metastases: The Anti-PD1 Brain Collaboration (ABC Study). GV Long, V Atkinson, AM Menzies, et al
TPS9598 A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). GV Long, R Dummer, A Ribas, et al
9511 A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. AN Shoushtari, RR Kudchadkar, K Panageas, et al
9513 KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. A Daud, CU Blank, C Robert, et al
9515 Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). AM Menzies, DB Johnson, S Ramanujam, et al
9516 Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. RR Munhoz, AN Shoushtari, D Kuk, et al
9517 Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). JS Weber, GT Gibney, RJ Sullivan, et al
9518 Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). FS Hodi, MA Postow, JA Chesney, et al
Monday June 6, 2016; 1:15 PM–4:15 PM
9500 Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. R Dummer, D Schadendorf, PA Ascierto, et al
9501 A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607). K Kalinsky, SJ Lee, KM Rubin, et al
9503 Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. C Robert, A Ribas, O Hamid, et al
9504 Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. J Schachter, A Ribas, GV Long, et al
9505 Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). JD Wolchok, V Chiarion-Sileni, R Gonzalez, et al
9507 Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM). KK Tsai, AN Shoushtari, RR Munhoz, et al
9508 Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. H Kaufman, JS Russell, O Hamid, et al
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: